Personalized medicine, in particular cell and gene therapy, is a relatively new class of therapeutics for which standardized production processes do not yet exist. Current processes for the production of ATMPs are often highly manual, therefore time-consuming and expensive. Consequently, many ATMPs are reserved for only a limited number of patients. To solve these problems, new smart approaches to automation are needed. We are proposing a modular approach where the production of CAR-T cells in a standardized form and with high quality at decentralized facilities should become a reality. In the presentation we would like to introduce you to our solution, the "mini-factory“ and the core elements of the concept: the modular approach, universal interfaces, robotic interlinking and automation of the process under GMP conditions.